JP7368670B2 - 破傷風毒素に対する完全天然型ヒト中和モノクロナル抗体及びその応用 - Google Patents

破傷風毒素に対する完全天然型ヒト中和モノクロナル抗体及びその応用 Download PDF

Info

Publication number
JP7368670B2
JP7368670B2 JP2020555284A JP2020555284A JP7368670B2 JP 7368670 B2 JP7368670 B2 JP 7368670B2 JP 2020555284 A JP2020555284 A JP 2020555284A JP 2020555284 A JP2020555284 A JP 2020555284A JP 7368670 B2 JP7368670 B2 JP 7368670B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
monoclonal antibody
set forth
neutralizing monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021508495A5 (https=
JP2021508495A (ja
Inventor
ホアシン リャオ
ユエミン ワン
シアオホイ ユアン
ウェイホン チョン
Original Assignee
チューハイ トリノマブ ファーマシューティカル カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201711482969.7A external-priority patent/CN108218984B/zh
Priority claimed from CN201711486732.6A external-priority patent/CN108314731B/zh
Priority claimed from CN201711486693.XA external-priority patent/CN108314730B/zh
Priority claimed from CN201810420730.5A external-priority patent/CN108623681B/zh
Application filed by チューハイ トリノマブ ファーマシューティカル カンパニー，リミティド filed Critical チューハイ トリノマブ ファーマシューティカル カンパニー，リミティド
Publication of JP2021508495A publication Critical patent/JP2021508495A/ja
Publication of JP2021508495A5 publication Critical patent/JP2021508495A5/ja
Application granted granted Critical
Publication of JP7368670B2 publication Critical patent/JP7368670B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020555284A 2017-12-29 2018-12-28 破傷風毒素に対する完全天然型ヒト中和モノクロナル抗体及びその応用 Active JP7368670B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201711482969.7A CN108218984B (zh) 2017-12-29 2017-12-29 一种抗破伤风毒素的全人源中和抗体
CN201711486732.6A CN108314731B (zh) 2017-12-29 2017-12-29 一种针对破伤风毒素的全人源单克隆中和抗体及其应用
CN201711486693.X 2017-12-29
CN201711482969.7 2017-12-29
CN201711486732.6 2017-12-29
CN201711486693.XA CN108314730B (zh) 2017-12-29 2017-12-29 抗破伤风毒素中和抗体及其制备与应用
CN201810420730.5 2018-05-04
CN201810420730.5A CN108623681B (zh) 2018-05-04 2018-05-04 一种抗破伤风毒素的中和抗体及应用
PCT/CN2018/124958 WO2019129214A1 (zh) 2017-12-29 2018-12-28 针对破伤风毒素的全人源单克隆中和抗体及其应用

Publications (3)

Publication Number Publication Date
JP2021508495A JP2021508495A (ja) 2021-03-11
JP2021508495A5 JP2021508495A5 (https=) 2023-05-30
JP7368670B2 true JP7368670B2 (ja) 2023-10-25

Family

ID=67063214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555284A Active JP7368670B2 (ja) 2017-12-29 2018-12-28 破傷風毒素に対する完全天然型ヒト中和モノクロナル抗体及びその応用

Country Status (6)

Country Link
US (1) US11725046B2 (https=)
EP (1) EP3733699A4 (https=)
JP (1) JP7368670B2 (https=)
AU (1) AU2018395100B2 (https=)
BR (1) BR112020013094A2 (https=)
WO (1) WO2019129214A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118139879A (zh) * 2021-09-07 2024-06-04 生物医学研究院 结合破伤风毒素的抗体及其用途
CN114044819B (zh) * 2021-09-29 2024-07-12 上海儒克生物科技有限公司 全羊源单克隆抗体的高通量制备方法
CN119700969A (zh) * 2023-09-27 2025-03-28 珠海泰诺麦博制药股份有限公司 一种抗破伤风毒素抗体在预防或治疗破伤风中的应用
CN118812707B (zh) * 2024-09-20 2024-12-31 北京科兴中维生物技术有限公司 抗破伤风毒素抗体及应用
CN120829503B (zh) * 2025-09-18 2025-12-26 北京科兴中维生物技术有限公司 抗破伤风毒素抗体及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001299360A (ja) 2000-04-28 2001-10-30 Morihiro Matsuda ヒト型抗破傷風毒素一本鎖組換え抗体フラグメント
CN1634991A (zh) 2003-12-30 2005-07-06 龚小迪 人源抗破伤风毒素单克隆抗体及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2627076B2 (ja) * 1988-08-19 1997-07-02 森永製菓株式会社 抗破傷風毒素ヒト型モノクローナル抗体、それを利用した破傷風毒素中和剤及びヒト型モノクローナル抗体産生ハイブリドーマ
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0562132T3 (da) * 1992-03-23 1999-03-22 Schweiz Serum & Impfinst Monoklonale antistoffer mod tetanustoksin og farmaceutiske præparater indeholdende dem
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
CN101220096B (zh) * 2003-12-30 2010-09-29 龚小迪 人源抗破伤风毒素单克隆抗体的制备和应用
CN105153305B (zh) * 2015-06-26 2019-03-01 安泰吉（北京）生物技术有限公司 一种全人源抗破伤风毒素单克隆抗体及其衍生物制备方法和应用
CN108314731B (zh) * 2017-12-29 2019-02-12 珠海泰诺麦博生物技术有限公司 一种针对破伤风毒素的全人源单克隆中和抗体及其应用
CN108314730B (zh) * 2017-12-29 2019-01-08 珠海泰诺麦博生物技术有限公司 抗破伤风毒素中和抗体及其制备与应用
CN108218984B (zh) * 2017-12-29 2018-10-26 珠海泰诺麦博生物技术有限公司 一种抗破伤风毒素的全人源中和抗体
CN108623681B (zh) * 2018-05-04 2019-05-24 珠海泰诺麦博生物技术有限公司 一种抗破伤风毒素的中和抗体及应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001299360A (ja) 2000-04-28 2001-10-30 Morihiro Matsuda ヒト型抗破傷風毒素一本鎖組換え抗体フラグメント
CN1634991A (zh) 2003-12-30 2005-07-06 龚小迪 人源抗破伤风毒素单克隆抗体及其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biologicals，2003年03月，Vol.31, No.1，pp.45-53

Also Published As

Publication number Publication date
AU2018395100A1 (en) 2020-07-23
EP3733699A1 (en) 2020-11-04
US11725046B2 (en) 2023-08-15
AU2018395100B2 (en) 2025-01-23
WO2019129214A1 (zh) 2019-07-04
JP2021508495A (ja) 2021-03-11
EP3733699A4 (en) 2022-06-08
BR112020013094A2 (pt) 2021-03-30
US20210002356A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
JP7368670B2 (ja) 破傷風毒素に対する完全天然型ヒト中和モノクロナル抗体及びその応用
US11512129B2 (en) TIGIT antibody, antigen-binding fragment thereof, and medical use thereof
US20220204621A1 (en) Bispecific antibodies to ror1 and cd3
TWI717678B (zh) Pd-l1抗體、其抗原結合片段及醫藥用途
TW201819413A (zh) Ｃｄ４７抗體、其抗原結合片段及其醫藥用途
AU2018202199A1 (en) Clostridium difficile antibodies
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
CN108218984B (zh) 一种抗破伤风毒素的全人源中和抗体
US20160215041A1 (en) Methods of Improving the Therapeutic Efficacy and Utility of Antibody Fragments
CN114390938A (zh) 受约束的条件性活化的结合蛋白
TW202031686A (zh) 抗ｃｄ７９ｂ抗體、其抗原結合片段及其醫藥用途
US20240239873A1 (en) Neutralizing antibodies to ebola virus glycoprotein and their use
TW202115125A (zh) 抗ｃｅａ抗體及其應用
CN112225813B (zh) 针对破伤风毒素的抗体及其用途
CN108314730A (zh) 抗破伤风毒素中和抗体及其制备与应用
CN103998059B (zh) 用于中和狂犬病病毒的结合分子
RU2815280C1 (ru) Антитело против столбнячного токсина и его применение
US20250011406A1 (en) Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
HK40071055A (en) Bispecific antibodies to ror1 and cd3
EP4646431A1 (en) Antibodies for zika virus
HK40017928B (en) Bispecific antibodies to ror1 and cd3
HK40017928A (en) Bispecific antibodies to ror1 and cd3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230221

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230913

R150 Certificate of patent or registration of utility model

Ref document number: 7368670

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150